NCT05843448View on ClinicalTrials.gov

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8
Interventions
BIOLOGICAL

PD-L1/IDO Peptide Vaccine

Given SC

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

IO Biotech
All Listed Sponsors
collaborator

IO Biotech

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

University of California, Davis

OTHER

NCT05843448 - IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter